Telomerase-dependent oncolytic adenovirus for cancer treatment
- 14 July 2003
- journal article
- Published by Springer Science and Business Media LLC in Gene Therapy
- Vol. 10 (15), 1241-1247
- https://doi.org/10.1038/sj.gt.3301987
Abstract
Conditionally replicative adenovirus (CRAD) is an attractive anticancer agent as it can selectively replicate in tumor cells. Expression of telomerase reverse transcriptase (TERT) is a unique tumor cell characteristic, being absent in normal postmitotic cells. Thus, we constructed a TERT promoter regulated CRAD for tumor-specific oncolysis by replacing the endogenous adenovirus E1A promoter with that of human TERT (Adv-TERTp-E1A). We showed that its replication was severely attenuated in TERT-negative cells, but that it replicated almost as efficiently as wild-type adenovirus in TERT-positive cells. Accordingly, Adv-TERTp-E1A conferred cytopathicity to TERT-positive, but not TERT-negative, cells. In vivo replication of Adv-TERTp-E1A after local administration into a xenograft model of human hepatocellular carcinoma in nude mice was demonstrated by an increase in adenovirus titers in tumor extracts by several orders of magnitude between 6 h and 3 days postvector injection. Furthermore, significant inhibition of tumor growth with substantial necrotic tumor areas staining positively for adenovirus was observed with Adv-TERTp-E1A, but not with a control replication-deficient adenovirus. There was also the absence of hepatotoxicity in tumor-bearing animals after intratumoral delivery of the CRAD. The results indicate that the TERT promoter-driven CRAD is capable of tumor-selective replication and oncolysis in vitro and in vivo, and can be utilized as an adjuvant treatment agent for cancer.Keywords
This publication has 24 references indexed in Scilit:
- E1B-55K-Deleted Adenovirus Expressing E1A-13S by AFP-Enhancer/Promoter Is Capable of Highly Specific Replication in AFP-Producing Hepatocellular Carcinoma and Eradication of Established TumorMolecular Therapy, 2002
- Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trialGene Therapy, 2001
- Analyses of Single-Amino-Acid Substitution Mutants of Adenovirus Type 5 E1B-55K ProteinJournal of Virology, 2001
- Telomerase and cancerHuman Molecular Genetics, 2001
- Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancerOncogene, 2000
- An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacyNature Medicine, 2000
- A Novel, Conditionally Replicative Adenovirus for the Treatment of Breast Cancer That Allows Controlled Replication of E1a-Deleted Adenoviral VectorsHuman Gene Therapy, 2000
- Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigenJCI Insight, 2000
- Replicative adenoviruses for cancer therapyNature Biotechnology, 2000
- An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor CellsScience, 1996